Endocrinology · INSR-Related Insulin Resistance

The INSR Severity Spectrum

At a Glance

INSR-related insulin resistance lies on a spectrum: near-total loss of receptor function causes severe Donohue syndrome, partial function is linked to Rabson-Mendenhall syndrome, and milder changes may cause Type A insulin resistance. Genetic results help classify risk but do not predict an exact course.

The medical community once viewed Donohue syndrome, Rabson-Mendenhall syndrome, and Type A insulin resistance as three distinct diseases. Today, research shows they are actually different overlapping phenotypes on a single severity spectrum of INSR-related receptor dysfunction ^[1]^[2].

This spectrum is defined by how much “working” insulin receptor function remains. A complete or near-total loss of function leads to the most severe symptoms, while retaining some residual receptor activity can change a person’s health trajectory ^[3]^[4]. Because this is a continuum, some patients may have features of two different syndromes or fall “in-between” the classic definitions ^[2]. These are descriptive clinical categories, not mandatory stages a person must progress through.

The Severity Matrix: Typical Patterns, Not Predictions

The following table compares the typical associations of the three main clinical categories. Individual variability is high, and a patient’s exact course depends on their variant, family history, and clinical care.

Feature	Donohue Syndrome	Rabson-Mendenhall	Type A Insulin Resistance
Usual Onset	Before or at birth ^[5]	Early childhood ^[6]	Puberty or adolescence ^[7]
Genetics	Typically Biallelic (2 mutations) ^[1]	Typically Biallelic (2 mutations) ^[1]	Often Heterozygous (1 mutation), but heterogeneous ^[8]
Growth	Severe restriction ^[9]	Short stature common ^[10]	Usually normal ^[11]
Key Signs	“Elfin” features, severe lipoatrophy ^[12]	Dental/nail abnormalities ^[13]	PCOS-like symptoms, hyperandrogenism ^[14]

Donohue Syndrome: The Severe End

Donohue syndrome is the most profound form of insulin receptor deficiency. It is typically diagnosed in the womb or shortly after birth due to severe growth restriction and a characteristic lack of body fat, which can make the skin appear loose and the muscles or veins very prominent ^[5]^[9].

Children with Donohue syndrome often face complex medical challenges beyond blood sugar, including an enlarged heart (hypertrophic cardiomyopathy) and kidney issues like calcium deposits (nephrocalcinosis) ^[15]^[16]^[12]. Historically, classic Donohue syndrome has been associated with a very shortened lifespan (often under two years), typically from infections or severe blood sugar crises ^[17]^[12]. However, every child is unique, and rare cases of survival into later childhood have been documented when some receptor function is present ^[2].

Rabson-Mendenhall Syndrome: The Intermediate Range

Rabson-Mendenhall syndrome (RMS) is considered intermediate in severity. While growth is often delayed, it is typically less extreme than in Donohue syndrome ^[6]^[10].

Distinguishing features of RMS often include teeth that come in very early, enlarged gums (gingival hyperplasia), and thickened or distorted nails ^[13]^[6]. Diabetes often develops during childhood or the teenage years and can be very difficult to control ^[6]^[18]. With modern intensive care, individuals with RMS frequently live into their 20s or 30s. The primary risks remain severe infections and a dangerous form of refractory acid buildup in the blood (DKA) ^[19]^[20].

Type A Insulin Resistance: The Milder Range

Type A is the most common and generally the mildest phenotype. It is often not suspected until puberty, when high insulin levels interfere with other hormones ^[7].

In females, the most common signs are related to hyperandrogenism (excess “male” hormones), such as severe acne, irregular periods, and polycystic ovaries ^[8]^[14]. Most individuals with Type A have a normal life expectancy ^[8]. Pregnancy is possible, though it requires specialized care due to the risks of gestational diabetes and potential growth impacts on the baby ^[8]^[21].

Genetics and the “Copy Number”

The severity of the syndrome is largely related to the genetic variant:

Biallelic (Recessive): Carrying two mutated copies (one from each parent) usually results in the more severe Donohue or Rabson-Mendenhall syndromes ^[1].
Monoallelic (Dominant) & Heterogeneous: Carrying one mutated copy typically leads to Type A insulin resistance, but Type A can also be caused by other genes or no identified variant ^[8].

Genetics is not always simple. Heterozygous variants have variable penetrance, and even within the same family, people with the identical mutation can have different levels of severity ^[22]. This suggests that other factors influence how the body handles insulin ^[23]^[24]. Always interpret these findings with a clinical geneticist.

Growth and Development Across the Spectrum

Because insulin pathways interact closely with growth pathways, these syndromes often lead to complex growth challenges ^[10]. This can result in short stature, delayed bone age, and unusual patterns of puberty ^[25]^[10]. Specialized endocrine monitoring is essential to track IGF-1 levels, bone age, and pubertal development to support the best possible growth without unnecessarily risking metabolic stability ^[26].

Common questions in this guide

What is the INSR severity spectrum?

The INSR severity spectrum describes how much working insulin receptor function remains in a person with INSR-related insulin resistance. Near-total loss is associated with Donohue syndrome, intermediate function with Rabson-Mendenhall syndrome, and milder or variable dysfunction with Type A insulin resistance. These are descriptive clinical patterns, not stages everyone must pass through.

How do Donohue syndrome, Rabson-Mendenhall syndrome, and Type A insulin resistance differ?

Donohue syndrome usually begins before or at birth and may cause severe growth restriction and very little body fat. Rabson-Mendenhall syndrome often begins in early childhood and may include growth delay, early teeth, enlarged gums, and nail changes. Type A insulin resistance is often recognized around puberty and commonly causes high insulin levels and hormone-related symptoms, especially in females.

Does having one or two INSR variants determine how severe the condition will be?

Two disease-causing INSR variants, one inherited from each parent, are more often associated with Donohue or Rabson-Mendenhall syndrome. One variant is often associated with Type A insulin resistance, but this relationship is not absolute because the same variant can affect family members differently and Type A may involve other genes or no identified variant. A clinical geneticist should interpret the result together with the person's symptoms.

What health problems can severe INSR deficiency cause?

Severe INSR deficiency can affect more than blood sugar. Donohue syndrome may involve severe growth restriction, loss of body fat, an enlarged heart, and calcium deposits in the kidneys; people with Rabson-Mendenhall syndrome may face severe diabetes, infections, and diabetic ketoacidosis. The specific risks depend on how much the insulin receptor still works and on the person's clinical course.

How can INSR-related insulin resistance affect growth and puberty?

INSR-related disorders can cause short stature, delayed bone age, and unusual timing of puberty. Endocrine follow-up may track growth, insulin-like growth factor 1, bone age, and pubertal development. Monitoring helps the care team support growth while avoiding unnecessary disruption of metabolic stability.

Can someone with Type A insulin resistance become pregnant?

Pregnancy is possible for people with Type A insulin resistance, but it should be planned with an experienced medical team. Pregnancy can increase the risk of gestational diabetes and may affect the baby's growth, so glucose, maternal health, and fetal growth need specialized monitoring.

How does INSR deficiency affect life expectancy?

Outlook varies widely across the INSR spectrum. Classic Donohue syndrome has historically been associated with a very short lifespan, while some children with residual receptor function survive longer; people with Rabson-Mendenhall syndrome may live into adulthood with intensive care, and Type A insulin resistance usually has a normal life expectancy. These patterns are not individual predictions, so prognosis should be discussed with the treating team.

Get notified when new evidence is published on Hyperinsulinism due to INSR deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

INSR-related receptor dysfunction is a continuum rather than three fixed stages that every person must progress through.
Donohue syndrome is the most severe phenotype and may cause severe growth restriction, loss of body fat, heart problems, and kidney complications from early life.
Rabson-Mendenhall syndrome is an intermediate phenotype often associated with growth delay, early teeth, enlarged gums, nail changes, and difficult-to-control diabetes.
Type A insulin resistance is generally the mildest phenotype, often recognized around puberty through high insulin levels and hormone-related symptoms such as hyperandrogenism.
Biallelic INSR variants are more often associated with severe phenotypes and heterozygous variants with Type A insulin resistance, but genetics alone cannot predict an individual's course.

References (26)

1
New classification and diagnostic criteria for insulin resistance syndrome.
Ogawa W, Araki E, Ishigaki Y, et al.
Endocrine journal 2022; (69(2)):107-113 doi:10.1507/endocrj.EJ21-0725.
PMID: 35110500
2
A novel homozygous missense mutation in the insulin receptor gene results in an atypical presentation of Rabson-Mendenhall syndrome.
Ben Abdelaziz R, Ben Chehida A, Azzouz H, et al.
European journal of medical genetics 2016; (59(1)):16-9.
PMID: 26691667
3
Deep mutational scanning of the human insulin receptor ectodomain to inform precision therapy for insulin resistance.
Aslanzadeh V, Brierley GV, Kumar R, et al.
Nature communications 2025; (16(1)):9143 doi:10.1038/s41467-025-64178-4.
PMID: 41093840
4
Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature.
Plamper M, Gohlke B, Schreiner F, Woelfle J
International journal of molecular sciences 2018; (19(5)) doi:10.3390/ijms19051268.
PMID: 29695048
5
Donohue syndrome: a new case with a new complication.
Odeh R, Alassaf A, Al-Qudah AA
Journal of pediatric endocrinology & metabolism : JPEM 2015; (28(7-8)):951-4.
PMID: 25741786
6
Rabson-Mendenhall Syndrome: Analysis of the Clinical Characteristics and Gene Mutations in 42 Patients.
Gong W, Chen W, Dong J, Liao L
Journal of the Endocrine Society 2024; (8(8)):bvae123 doi:10.1210/jendso/bvae123.
PMID: 38957655
7
Type A insulin resistance syndrome misdiagnosed as polycystic ovary syndrome: a case report.
Lin L, Chen C, Fang T, et al.
Journal of medical case reports 2019; (13(1)):347 doi:10.1186/s13256-019-2304-4.
PMID: 31771632
8
Comprehensive assessment of the genotype-phenotype spectrum and treatment for monoallelic insulin receptoropathy in a cohort of 505 people.
Brown RJ, Xu J, Luan J, et al.
Research square 2026; doi:10.21203/rs.3.rs-10884175/v1.
PMID: 42856426
9
A case of Donohue syndrome "Leprechaunism" with a novel mutation in the insulin receptor gene.
Kirel B, Bozdağ Ö, Köşger P, et al.
Turk pediatri arsivi 2017; (52(4)):226-230 doi:10.5152/TurkPediatriArs.2017.3193.
PMID: 29483803
10
Long-Term Effects of Metreleptin in Rabson-Mendenhall Syndrome on Glycemia, Growth, and Kidney Function.
Okawa MC, Cochran E, Lightbourne M, Brown RJ
The Journal of clinical endocrinology and metabolism 2022; (107(3)):e1032-e1046 doi:10.1210/clinem/dgab782.
PMID: 34718628
11
Clinical characteristics of adolescent cases with Type A insulin resistance syndrome caused by heterozygous mutations in the β-subunit of the insulin receptor (INSR) gene.
Takasawa K, Tsuji-Hosokawa A, Takishima S, et al.
Journal of diabetes 2019; (11(1)):46-54 doi:10.1111/1753-0407.12797.
PMID: 29877041
12
Duodenogastric Intussusception in a 14-Week-Old Infant with Donohue Syndrome: Case Study.
Nicolescu CR, Cremillieux C, Stephan JL
Case reports in pediatrics 2023; (2023()):7799234 doi:10.1155/2023/7799234.
PMID: 37885901
13
Arg924X homozygous mutation in insulin receptor gene in a Tunisian patient with Donohue syndrome.
Azzabi O, Jilani H, Rejeb I, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(6)):753-6.
PMID: 26974131
14
Identification of a Novel Mutation in Patients with Type A Insulin Resistance Syndrome.
Zhao L, Dai H, Zhang Q, et al.
Human heredity 2022; (87(2)):60-68 doi:10.1159/000525223.
PMID: 35661079
15
Hypertrophic cardiomyopathy in Donohue syndrome.
Termote JU, Breur JM, de Vroede MA
Cardiology in the young 2016; (26(4)):815-8 doi:10.1017/S1047951115002437.
PMID: 26555333
16
Gastrointestinal dysmotility and pancreatic insufficiency in 2 siblings with Donohue syndrome.
Kostopoulou E, Shah P, Ahmad N, et al.
Pediatric diabetes 2017; (18(8)):839-843 doi:10.1111/pedi.12483.
PMID: 28004474
17
[Donohue syndrome and use of continuous subcutaneous IGF1 pump therapy].
Melikyan MA, Ivannikova TE, Milovanova NV, et al.
Problemy endokrinologii 2022; (68(5)):79-86 doi:10.14341/probl13121.
PMID: 36337021
18
Rabson-Mendenhall syndrome caused by a novel splice-site mutation (c.1123+2 T>C) of insulin receptor: A case report and review of literature.
Wang K, Zheng J, Gu LC, et al.
World journal of diabetes 2026; (17(1)):113821 doi:10.4239/wjd.v17.i1.113821.
PMID: 41608093
19
Case Report: Tirzepatide improves glycemic control in Rabson-Mendenhall syndrome.
Araújo-Vilar D, Vela A, Castro AI, et al.
Frontiers in endocrinology 2026; (17()):1945251 doi:10.3389/fendo.2026.1945251.
PMID: 42729636
20
Rabson-Mendenhall Syndrome Nearly Misdiagnosed as Type 1 Diabetes Mellitus: A Case Report.
Almotawa F, Mushiba AM, Alqahtani N, Mashi A
Cureus 2025; (17(3)):e81190 doi:10.7759/cureus.81190.
PMID: 40144769
21
Case report: Glycaemic management and pregnancy outcomes in a woman with an insulin receptor mutation, p.Met1180Lys.
Crowley MT, Goulden E, Sanchez-Lechuga B, et al.
Clinical diabetes and endocrinology 2024; (10(1)):5 doi:10.1186/s40842-024-00166-9.
PMID: 38461278
22
Family with two novel in cis INSR gene variants: Phenotypic evolution with age.
Sotiriou G, Mertzanian A, Raptopoulou ME, et al.
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2026; (35(4)):351-356 doi:10.1297/cpe.2026-0014.
PMID: 42825299
23
A family with type A insulin resistance syndrome caused by a novel insulin receptor mutation.
Horikawa O, Ugi S, Takayoshi T, et al.
Endocrinology, diabetes & metabolism case reports 2023; (2023(2)).
PMID: 37042492
24
Hyperinsulinemic hypoglycemia due to pathogenic INSR variants: metabolic signature, phenotypic overlap, and semidominant inheritance.
Marcelino do Nascimento R, Dos Santos A, Guadagnini D, et al.
Frontiers in endocrinology 2026; (17()):1716020 doi:10.3389/fendo.2026.1716020.
PMID: 42181197
25
Primary Care Recognition of Rabson-Mendenhall Syndrome Despite Absence of Classical Diabetic Symptoms.
Al Eisa A, Aldayhani AH
The American journal of case reports 2026; (27()):e953067 doi:10.12659/AJCR.953067.
PMID: 42700438
26
Rabson-Mendenhall Syndrome in a brother-sister pair in Kuwait: Diagnosis and 5 year follow up.
Al-Kandari H, Al-Abdulrazzaq D, Al-Jaser F, et al.
Primary care diabetes 2021; (15(1)):175-177 doi:10.1016/j.pcd.2020.07.012.
PMID: 32843252

This page is for informational purposes only and does not replace medical advice about INSR-related insulin resistance. A clinical geneticist and endocrinology team should interpret your genetic results and guide care for you or your child.